ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatitis C"

  • 2020 American Transplant Congress

    Highly Effective Short Course Therapy to Prevent Infection after Transplantation from HCV-Infected Organ Donors to Uninfected Recipients across Multiple Organ Types

    A. Humar1, M. Cypel1, D. Kumar1, H. Dahari2, R. Vanin Pinto Ribeiro1, N. Marks1, N. Kamkar1, I. Bahinskaya1, F. Onofrio3, M. A. Zahoor3, O. Cerrochi3, K. Tinckam1, S. J. Kim1, T. W. Reichman1, M. McDonald1, T. K. Waddell1, G. Sapisochin1, M. Selzner1, S. Keshavjee1, H. L. Janssen3, B. E. Hansen3, L. Singer1, J. Feld3

    1Transplant Centre, Toronto General Hospital, Toronto, ON, Canada, 2Loyala University, Chicago, IL, 3Toronto General Hospital, Toronto, ON, Canada

    *Purpose: An increasing percentage of potential organ donors are infected with hepatitis C virus (HCV). Establishment of HCV infection in uninfected recipients is near-universal with…
  • 2020 American Transplant Congress

    Does Transplantation of Hepatitis C Infected Kidneys Into Uninfected Recipients Cause Hepatitis C-Associated Kidney Injury?

    R. H. Naik, S. Shawar, R. C. Forbes, H. Schaefer, D. Shaffer, M. Rossi, V. Imperio, B. P. Concepcion, M. Kapp

    Vanderbilt University Medical Center, Nashville, TN

    *Purpose: With increasing utilization of Hepatitis C infected (HCV+) kidneys for transplantation into uninfected (HCV-) recipients, there is concern for the development of HCV-associated kidney…
  • 2020 American Transplant Congress

    Association between Ezetimibe Usage and Hepatitis C RNA Levels in Uninfected Kidney Transplant Recipients Who Received Hepatitis C Infected Kidneys

    A. Azhar, M. Yazawa, M. Talwar, V. Balaraman, A. Bhalla, U. A. Agbim, B. Maliakkal, J. P. Kothadia, S. Nair, J. D. Eason, M. Z. Molnar

    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN

    *Purpose: Our previous data showed that transplantation of kidneys from hepatitis C virus (HCV) infected donors to HCV negative recipients achieved excellent short-term graft function,…
  • 2020 American Transplant Congress

    Feasibilty of Hepatitis C NAT Positive Kidney Transplant into Hepatitis C Negative Recipients as Standard of Care

    T. Kaur, J. Choi, N. Anwar, M. Anand, S. Shah, S. Bumb, B. Abu Jawdeh, S. Shah, T. Diwan, A. Govil

    University of Cincinnati Medical Center, Cincinnati, OH

    *Purpose: With advent of direct acting antivirals (DAA) for Hepatitis (Hep) C which have a 96-100% sustained viral remission(SVR), doors have opened for using Hep…
  • 2020 American Transplant Congress

    Fibrosing Cholestatic Hepatatitis in Post Renal Transplant and Successful Treatment with Newer DAA Therapy

    V. Siddini

    Nephrology, Manipal Hospital, Bangalore, India

    *Purpose: Fibrosing cholestatic hepatitis is often fatal post renal transplantation. we report a case of successful treatment of FCH and complete recovery*Methods: A 53 year…
  • 2020 American Transplant Congress

    Comparable Outcomes for Simultaneous Liver-Kidney Transplantation with HCV NAT-Positive Donors

    M. L. Samoylova1, B. I. Shaw1, S. J. Kesseli1, L. McElroy1, Y. Patel2, S. Sanoff2, A. S. Barbas1

    1Surgery, Duke University Hospital, Durham, NC, 2Medicine, Duke University Hospital, Durham, NC

    *Purpose: To evaluate the impact of hepatitis C virus (HCV) Nucleic Acid Amplification-positive (NAT+) donors on outcomes following simultaneous liver-kidney (SLK) transplantation.*Methods: We used the…
  • 2020 American Transplant Congress

    Anticipated Cost Savings of Using Lungs from Hepatitis C-Positive Lung Donors for Hepatitis C-Negative Recipients

    K. Ryland1, J. Mallea2, J. Moriarty3, L. White4, B. Borah5, J. Naessens3

    1Transplantation, Mayo Clinic, Jacksonville, FL, 2Medicine, Mayo Clinic, Jacksonville, FL, 3Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, 4Health Sciences Research, Mayo Clinic, Jacksonville, FL, 5Health Sciences Research, Mayo Clinic, Rochester, MN

    *Purpose: We assessed the cost savings generated by additional organ availability due to utilizing lungs from hepatitis-C infected donors for transplantation in comparison to existing…
  • 2020 American Transplant Congress

    Preemptive Direct Acting Antiviral Therapy as Prophylaxis in Donor HCV-Positive to Recipient HCV-Negative Solid Organ Transplant: a Comprehensive Review

    M. Mavuram, S. Mavuram, H. Samant, S. Pandit, B. Samant, J. Morris, J. Alexander

    Gastroenterology, Louisiana State University of Health Sciences Shreveport, Shreveport, LA

    *Purpose: With the advent of highly effective and safe oral Direct acting Antiviral agents (DAAs), several transplant centers have adopted protocols for using HCV positive…
  • 2020 American Transplant Congress

    Lowering Meld, Diminishing Length of Stay, and Increasing Liver Transplant Numbers Comes Through the Generosity of Others: Declined HCV-NAT Offers Subsequently Transplanted Have Excellent Outcomes

    R. Gilroy, S. Sell, J. Krong, A. Gagnon, I. Zendejas, S. Fujita, M. Rodriguez, D. Alonso

    Transplant Services, Intermountain Healthcare, Murray, UT

    *Purpose: There is variability between programs in the acceptance of organ offers. This paper examines offer, acceptance and program performance with HCV NAT positive donor…
  • 2019 American Transplant Congress

    Transplanting Thoracic Organs From Hcv Donors To Uninfected Patients: Evaluation Of Lung Allografts

    Y. Lo1, R. F. Padera1, H. R. Mallidi2, H. J. Goldberg3, S. K. Singh2, A. Coppolino, III4, L. R. Baden5, A. E. Woolley5

    1Pathology, Brigham and Womens Hospital, Boston, MA, 2Cardiac and Thoracic Surgery, Brigham and Womens Hospital, Boston, MA, 3Pulmonary, Brigham and Womens Hospital, Boston, MA, 4Thoracic Surgery, Brigham and Womens Hospital, Boston, MA, 5Infectious Diseases, Brigham and Womens Hospital, Boston, MA

    *Purpose: Prior to the development of direct acting antiviral (DAA) therapy for hepatitis C virus (HCV), there was concern that patients who received lungs from…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 28
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences